Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual dysfunction, with estimates of prevalence approximating 10%. By definition it is a deficiency of sexual desire that causes distress. HSDD has no single cause, but physiological, psychological and socio-cultural factors underpinning female sexual desire may all be important in its development.
INTRODUCTION
Hypoactive sexual desire disorder (HSDD) in women is, at its most basic level, a lack of sexual desire that causes distress. The most recent edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM IV-TR) defines HSDD as: 'Persistent or recurrently deficient (or absent) sexual fantasies and desire for sexual activity. The disturbance causes marked distress or interpersonal difficulty', and 'is not due exclusively to the direct physiological effects of a substance or a general medical condition' [1] . HSDD has been included in the International Classification of Diseases (ICD-10, F52.0) and has also been defined by the American Urological Association Foundation [2] . The latter organization has further recommended that for any diagnosis of dysfunction the following should be considered: whether the dysfunction is lifelong or acquired, generalized or situational; the degree of distress experienced, and if any negative contextual factors are present (relationship, environment, etc.) [2] . HSDD receives particular attention under the banner of female sexual dysfunction due to its higher prevalence. Estimates of HSDD vary widely according to the population studied, menopausal status, whether menopause was natural or surgical and the criteria used to define HSDD, but it is thought that anywhere between 7 and 26% of women experience HSDD [3 && ,4-7]. A recent health policy statement from the International Society of Sexual Medicine (ISSM) on HSDD quotes a figure of 10% of women across all age groups [8 && ]. HSDD often occurs in association with other female sexual dysfunctions, such as arousal or lubrication problems, particularly in individuals who rate their HSDD as being severe [9 & ]. Whereas no single causative factor has been identified in HSDD, a considerable amount of research has been performed in the past 15-30 years, with a focus on the exploration of the physiological, psychological and socio-cultural aspects of female sexual desire.
DOES IT EXIST AT ALL?
HSDD was first defined in DSM III-R [10] , and the precursor terms 'inhibited sexual desire disorder' and 'hypoactive sexual desire' were reported by independent researchers in 1977 [11, 12] . Whether HSDD actually exists at all is a topic of hot debate. Some critics have claimed that the concept of 'female sexual dysfunction' has been a joint manufacture by self-interested medical and pharmaceutical personnel who may gain financial benefit from the diagnosis and treatment of women with sexual issues [13] . Others argue strongly that not only does female sexual dysfunction exist, but the element of distress associated with the dysfunction may be in some cases severe and debilitating with the potential for deleterious effects on women's overall health and relationships [8 && ]. There seems to be general agreement that HSDD in its current form is imperfectly named and defined [14] , with proposed revisions currently under debate for inclusion in the upcoming DSM-V in 2012 [15,16 && ]. The salient issues under review are the following: whether the inclusion of sexual fantasies and the element of distress are necessary; whether 'responsive desire' should be added; how to include the overlap between sexual arousal and desire and how to include the influences and consequences of relationships [17] .
SEXUAL DESIRE IN WOMEN
Sexual desire has been described as 'a biological drive subject to both endocrine fluctuations and the complex neural activity of the brain' [18] . The subjective experience of sexual desire for an individual is thought to result from a complex relationship between excitatory and inhibitory forces [19] . Sexual function in women diminishes with age [20, 21] , as does sexual desire [22] . Longer relationship duration has also been associated with a decrease in sexual desire, which seems to preferentially affect women [23] . Although sexual function and desire decline with age, evidence suggests that the prevalence of distress associated with these changes is higher in younger women [22,24 & ], which may reflect the higher importance of sexual function to reproductive aged women, and potentially other factors that may be more prevalent in older women and their partners, such as medication use and comorbidities. The Study of Women Across the Nation (SWAN) reported the presence of little or no spontaneous sexual desire in over 3000 women at midlife, yet satisfaction with sexual function was intact [25] , suggesting that the distress associated with lowered sexual desire in some women only affects a small subgroup of the population.
HORMONAL FACTORS: SEX STEROID HORMONES
The age-related changes in sexual function in women are proposed to have a physiological basis, theorized to be due to the marked fall in oestradiol levels around and beyond the time of menopause [26] , with the age-related decline in androgen levels also likely to be contributing [27] . Whereas the fall in oestradiol levels around menopause is associated in the majority of women with a varying incidence and severity of somatic symptoms that may contribute to lowered libido, including sleep deprivation and vaginal dryness, the fall in androgens is more gradual, with a steep decline in testosterone and precursor hormones seen even from adult women in the early reproductive years [27] . Testosterone levels at age 40 are on average half of those at 20 years, and continue to fall until a nadir is reached at age 65. Bilateral oophorectomy is further associated with a 50% or more reduction in androgen levels [28] , and a higher prevalence of HSDD in some studies, particularly in younger women [4] [5] [6] . Whereas a link between testosterone precursor hormones and aspects of sexual function has been made, the largest cross-sectional study reporting sexual desire in relation to androgen levels in women has not made a link with endogenous testosterone levels [29] . It is possible, however, that the combination of the fall in oestradiol levels around the time of menopause and the age-related decline in androgen levels in some women may cause them to be highly susceptible to a fall in sexual desire and in those cases that cause distress, a diagnosis of HSDD.
NEUROTRANSMITTERS, OTHER HORMONES AND PEPTIDES
Several other biologically active entities are believed to have an important role in sexual function in women, including the pro-sexual effects of dopamine [30] , noradrenaline [31] , melanocortins, serotonin
KEY POINTS
Hypoactive sexual desire disorder (HSDD) is an evolving diagnosis with much debate over the criteria for diagnosis.
HSDD is the most prevalent female sexual dysfunction and affects approximately 10% of women.
Treatment strategies for HSDD are limited and have focused on hormonal modulation and cognitive behavioural strategies.
acting via 5-hydroxytryptamine 1A (5-HT 1A ) and 5-HT 2C [32] , and oxytocin [33] . Gamma-amino butyric acid has an inhibitory effect on sexual function as does the action of serotonin at other receptors [34] . In recent years these molecules or associated pathways have provided a focus for the development of medical therapies for HSDD. It is proposed that a complex relationship between neurotransmitters, various peptides and hormones exists with other factors, such as the environment, with regard to the net effect on sexual function [35] .
PSYCHOLOGICAL FACTORS
Using the incentive motivation model of sexual function, it has been hypothesized that HSDD may result from weakening of the association between sexual stimuli and rewarding experiences [36 & ]. In an attempt to map neural pathways in women with HSDD, a study using functional MRI has reported less activation in brain areas involved in the processing of erotic stimuli, comparing a group of women with HSDD versus a control group. An additional finding in women with HSDD included increased activation in brain areas associated with higher-order social and cognitive functions, suggesting that women with HSDD process sexual stimuli in a different way to nonaffected women [37 & ]. Some hypothesize, however, that the distress element of female sexual dysfunction may be less related to the sexual dysfunction and more related to other psychological factors and general anxiety [38 && ].
THERAPEUTIC STRATEGIES: HRT
Therapeutic strategies for impaired sexual function have included, in peri or postmenopausal women, the introduction of vaginal or systemic oestrogen therapy (the latter including progestogen treatment in those with intact uteri). Systemic HRT is effective in treating vasomotor and other symptoms around the time of the menopause, and may have an effect on sexual desire indirectly by reducing vasomotor symptoms, improving sleep quality and general wellbeing [39 && ]. Similarly, vaginal oestrogen is effective in addressing vaginal dryness due to atrophic changes, which may secondarily improve sexual desire. Whilst HRT users in some studies have been reported to have higher sexual desire compared to nonusers [5, 40] , a similar effect of HRT was not seen for those who met the criteria for HSDD [5] . Overall there is no evidence to suggest there is a significant effect of HRT on sexual desire, arousal and orgasmic response [41 && ].
ANDROGENS
The majority of studies of androgen therapy have been of testosterone, administered by tablet, injection, subcutaneous pellet or 'implant' and, in more recent studies, transdermal patch, cream or gel. Most studies have been performed in surgically postmenopausal women, and have involved dosing with testosterone in addition to systemic oestrogen. A Cochrane review of testosterone in combination with systemic HRT compared to HRT alone reported that testosterone was associated with significant improvements in a number of sexual function parameters, including the number of satisfying sexual events and sexual desire [42] . More recent studies of testosterone have been in naturally menopausal women [43] , and of testosterone use alone [44] . Only a few studies have been performed in premenopausal women [45] [46] [47] . In the majority of studies of testosterone an improvement in sexual function has been reported, including in more recent studies the number of satisfying sexual events, the criteria by which the US Food and Drug Administration (FDA) draft guidance for clinical trials in the area of female sexual dysfunction has specified an improvement should be seen [48] . Side effects are in general minimal, with those most frequently reported from randomized placebocontrolled trials including increased hair growth and acne [49 && ]. The criticisms of studies of testosterone use in women have included the use of supraphysiological doses of testosterone, the presence of a strong placebo response, scant data in premenopausal women and a lack of data on long-term effects [50 && ]. In answer to the latter criticism one study of a large cohort of women who had used testosterone for a median of 1.3 years reported no increase in the incidence of breast cancer [51] , and the longest follow-up of women using testosterone for 4 years was recently reported, with the most common adverse effects including application site reactions and unwanted hair growth [52 && ]. The other pertinent issue in studies of testosterone in women is whether improvements in sexual function are a direct effect, or due secondarily to improvements in well being [53] .
Paradoxically there are no approved products for testosterone use in women in some countries which have been active in the area of testosterone research in women, including the US and Australia. A twiceweekly transdermal testosterone patch has been approved in the UK and Europe for the treatment of surgically menopausal women with HSDD, and other forms of testosterone treatment in development/under application for therapeutic approval in women include transdermal delivery via a gel, spray and cream [46, 54 
DEHYDROEPIANDROSTERONE ACETATE
Some studies have explored the effects of the testosterone precursor hormone dehydroepiandrosterone acetate (DHEA) on female sexual function. Whilst a link has been described between endogenous serum levels of DHEAS (the sulphated version of DHEA) and sexual desire, arousal and responsiveness in women below 45 years of age, and sexual responsiveness in women at least 45 years of age [29] , placebo-controlled studies do not report an improvement in sexual function in women treated with physiological doses of DHEA [56] . Despite the lack of efficacy with DHEA in clinical studies of sexual function, DHEA is a commonly used 'overthe-counter' preparation that may also be prescribed in some countries, in the belief that it improves sexual function in addition to other parameters such as memory or well being [57] .
BUPROPION
Bupropion is an antidepressant agent which functions as a dopamine agonist by blocking dopamine and noradrenaline re-uptake. Whereas combination treatment with a selective serotonin reuptake inhibitor (SSRI) resulted in an increase in sexual desire in one study [58] , a lack of effect on sexual desire was seen with bupropion in women with HSDD [59] . The latter study did, however, report increases in sexual receptivity and arousability associated with bupropion use in women with HSDD.
FLIBANSERIN
Flibanserin acts as a postsynaptic agonist at the 5-HT 1A receptor, and an antagonist at the 5-HT 2C receptor [60 && ]. In studies of premenopausal women with HSDD 100 mg of flibanserin was consistently associated with improvements in sexual desire and satisfying sexual events, in addition to reduced levels of sexual distress, compared with women
Fatigue, somnolence and dizziness were reported in around 10% of participants on flibanserin, and this medication is yet to be approved for the treatment of HSDD.
GEPIRONE
Gepirone is a selective 5-HT 1A receptor partial agonist that is under development for the treatment of anxiety and depression. Gepirone has been associated with a higher rate of reversal of HSDD when compared to placebo and SSRI-treated, mostly premenopausal, women with depression [64 & ].
PSYCHOLOGICAL INTERVENTIONS
Cognitive behavioural therapy may be a useful strategy in HSDD, especially in those women who have lowered mood, depression or anxiety. Few studies of psychological therapeutic interventions have been performed and an urgent need for randomized controlled studies for women with low desire has been identified [14, 65] . Improved sexual function scores were reported in women with sexual dysfunction who underwent a group psychoeducational intervention [66] . Similarly, a study of group cognitive behavioural therapy in couples reported an improvement in sexual desire that was maintained in over 60% at 1 year [67] . An internet-based psychological treatment program consisting of communication skills training, sensate focus exercises and contact with a therapist in women with female sexual dysfunction versus controls has reported improved sexual and relationship functioning in the treatment group 
CONCLUSION
Female sexual dysfunction is an evolving area in women's health. HSDD is the most prevalent female sexual dysfunction, affecting approximately 10% of women, and there continues to be a debate about whether the entity actually exists, the appropriate name for the condition and the criteria for diagnosis. Treatment options are limited and the focus to date has been on the addition of testosterone treatment to HRT in surgically postmenopausal women, which has consistently been associated with improvements in sexual function in women with HSDD.
The most important issue in women with HSDD, however, as a consensus on diagnostic and other criteria continues to be debated, is the recognition that a certain percentage of premenopausal and postmenopausal women have sexual desire issues which cause them distress and can significantly impinge on their quality of life and relationships. The focus in this area of women's health should therefore be on the ongoing research of effective treatment modalities, both medical and psychological.
